Skip to main content

OptimizeRx Corporation (OPRX) Stock Forecast

Data as of Oct 31, 2026

Healthcare · Current price $9.22 (-1.55%)

Consensus Target
$10.25
Upside
+11.1%
Analysts
4
Rating
Buy(2.25)

Price Target Range

Low $7.00Consensus $10.25High $12.00
▲ Current $9.22

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Mar 6, 2026David GrossmanStifel Nicolaus$17.00+84.3%
Apr 4, 2024Constantine DavidesJMP Securities$15.00+62.6%

OPRX vs Sector & Market

MetricOPRXHealthcare AvgLarge Cap Avg
Analyst Rating2.252.252.41
Analyst Count4819
Target Upside+11.1%+153002.0%+21.5%
P/E Ratio26.043.4538.49

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$34M$38M$40M2
2027-03-31$17M$19M$21M2
2027-06-30$24M$27M$29M2
2027-09-30$28M$32M$34M2
2027-12-31$36M$40M$43M2

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$0.43$0.50$0.552
2027-03-31$0.02$0.03$0.032
2027-06-30$0.16$0.18$0.201
2027-09-30$0.26$0.31$0.331
2027-12-31$0.48$0.56$0.612

Frequently Asked Questions

What is the analyst consensus for OPRX?

The consensus among 4 analysts covering OptimizeRx Corporation (OPRX) is Buy with an average price target of $10.25.

What is the highest price target for OPRX?

The highest price target for OPRX is $17.00, set by David Grossman at Stifel Nicolaus on 2026-03-06.

What is the lowest price target for OPRX?

The lowest price target for OPRX is $15.00, set by Constantine Davides at JMP Securities on 2024-04-04.

How many analysts cover OPRX?

4 analysts have issued ratings for OptimizeRx Corporation in the past 12 months.

Is OPRX a buy or sell right now?

Based on 4 analyst ratings, OPRX has a consensus rating of Buy (2.25/5) with a +11.1% upside to the consensus target of $10.25.

What are the earnings estimates for OPRX?

Analysts estimate OPRX will report EPS of $0.50 for the period ending 2026-12-31, with revenue estimated at $38M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.